Nafamostat mesylate (INN), a synthetic serine protease inhibitor, is a short-acting anticoagulant, and it is also used for the treatment of pancreatitis. It also has some potential antiviral and anti-cancer properties. Nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. The mechanism of action of nafamostat is as a slow tight-binding substrate, trapping the target protein in the acyl-enzyme intermediate form, resulting in apparent observed inhibition.
via PubMed
{{Drugbox | Verifiedfields = changed | verifiedrevid = 444083240 | drug_name = Nafamostat mesylate | type = | IUPAC_name = 6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate | image = Nafamostat.svg | image_class = skin-invert-image
| alt = | caption = | tradename = | Drugs.com = | MedlinePlus = | licence_EU = | licence_US = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Rx-only | routes_of_administration = IV
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).